Viro-Immunological Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide among Women Living with HIV: A 96-Week Post-Switch Analysis from the Real-Life SHiNe-SHiC Cohort

Viro-Immunological Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide among Women Living with HIV: A 96-Week Post-Switch Analysis from the Real-Life SHiNe-SHiC Cohort

<b>Background/Objectives</b>: Out of 39.9 million adults living with HIV in 2022, 20 million were women. Despite bearing a significant burden, women remain underrepresented in clinical trials, including those for antiretroviral treatments (ART). This study evaluates the safety and effica...

Full description

Bibliographic Details
Main Authors: Agnese Colpani, Andrea De Vito, Andrea Marino, Manuela Ceccarelli, Benedetto Maurizio Celesia, Giuseppe Nicolò Conti, Serena Spampinato, Giulia Moi, Emmanuele Venanzi Rullo, Giovanni Francesco Pellicanò, Sonia Agata Sofia, Grazia Pantò, Carmelo Iacobello, Chiara Maria Frasca, Arturo Montineri, Antonio Albanese, Goffredo Angioni, Bruno Cacopardo, Giordano Madeddu, Giuseppe Nunnari, on behalf of Sardinian HIV Network and Sicilian HIV Cohort (SHiNe-SHiC) Research Group
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Biomedicines
Subjects:
HIV
bictegravir
AIDS
WLWH
women and HIV
TAF
Online Access:https://www.mdpi.com/2227-9059/12/10/2311

Internet

https://www.mdpi.com/2227-9059/12/10/2311

Similar Items